Webinar | Best Practices for Launching Profitable, Efficient NGS Tests for Hereditary Risk


Best Practices for Launching Profitable, Efficient NGS Tests for Hereditary Risk


This webinar will discuss the best practices for how molecular diagnostic labs can quickly and effectively launch next-generation sequencing (NGS) hereditary risk genetic testing. The webinar will explore how to implement an effective testing program, particularly market trends and considerations, laboratory setup and validation, data analysis, and reporting, and will share best practices for selecting and implementing a tertiary analysis pipeline for variant interpretation.

Clinical laboratories are rapidly expanding the scope and complexity of their hereditary testing services offered to utilize next-generation sequencing. With this expansion comes a significant number of challenges, including setup, panel design and validation, how to build for optimum turnaround time, and the need for specialized clinical genetic knowledge and overall scalability. A good strategy for selecting and implementing appropriate tertiary analysis tools and setting up a scalable interpretation workflow is critical to the success of a clinical NGS program.


Tootie Tatum, PhD headshot, Blackhawk Genomics

Tootie Tatum, PhD, Founder and CEO, Blackhawk Genomics

Tootie Tatum is the Founder and CEO of Blackhawk Genomics. A clinical genomic scientist with over 20 years of experience in molecular diagnostics in academic medical centers and commercial laboratories, she is one of a few individuals worldwide to have developed project management and workflow systems for large genome sequencing centers. Dr. Tatum currently serves on the American Board of Bioanalysis and is a Next-Generation Sequencing (NGS) and Molecular Pathology Specialty Inspector for the College of American Pathologists (CAP). She is also the CLIA laboratory director for the UPMC Genome Center and the Discovery Life Sciences Clinical Genomics Laboratory.

Charlene Son Rigby headshot, Fabric Genomics

Charlene Son Rigby, MBA, Chief Business Officer, Fabric Genomics

Charlene Son Rigby is responsible for customer success, business development, and regulatory at Fabric Genomics. She has spent her career building businesses at the intersection of data, technology, and life sciences. Before joining Fabric Genomics, Son Rigby was responsible for all go-to-market activities at Metamarkets, a big data analytics startup, was Vice President of Business Planning at Oracle, and Executive Director of Sales Operations at Siebel Systems, a $2B license business. Son Rigby also led product management at DoubleTwist, a bioinformatics startup. She started her career as a neuroscience researcher at Syntex (acquired by Roche). Son Rigby holds a BA in Human Biology from Stanford University and an MBA from the Haas School of Business at U.C. Berkeley.

Jeanette McCarthy, MPH, PhD headshot, round

Jeanette McCarthy, MPH, PhD, Senior Director, Scientific Programs, Fabric Genomics

Jeanette McCarthy is a genome scientist and educator working at the forefront of precision medicine implementation. As a faculty member at Duke University, she ran research programs on genetic underpinnings of complex diseases, both infectious and chronic. In 2013 she founded Precision Medicine Advisors, an education and consulting business focused on communicating genomics to non-technical audiences, including health care providers, patients and other stakeholders. Jeanette has worked with Fabric Genomics since 2013 on the development of software for genome analysis and variant interpretation and currently leads scientific programs and clinical services. Jeanette is coauthor of the book, Precision Medicine: A Guide to Genomics in Clinical Practice (2016, McGraw Hill Education).

Turn your diagnostic odysseys into answers